Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19
N/A
The goal of this study is to assess serious adverse events associated with ...
Status
Completed
Location
CMIC Co., Ltd
Start Date
2022-11-15
Trial ID
NCT05894590
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
PHASE3
The purpose of this study is to evaluate the immunogenicity, safety, and re...
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
PHASE1
The primary goal for this study is to evaluate the safety and reactogenicit...
Status
Completed
Location
Synexus Clinical Research US Phoenix Southeast, Inc.
Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination
PHASE2
The objective will be to analyze the development of cellular and humoral im...